Relative Bioavailability of BI 10773 Administered Twice Daily Compared BI 10773 Given Once Daily After Multiple Oral Doses in Healthy Male and Female Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2009

Conditions

Healthy

Interventions

DRUG

Empagliflozin

5 days of treatment with 5 mg BI 10773 bid until steady state

DRUG

Empagliflozin

5 days of treatment with 10 mg BI 10773 qd until steady state

Trial Locations (1)

1276.9.1 Boehringer Ingelheim Investigational Site, Biberach